These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 28115471)

  • 1. Two-year outcomes of bioresorbable vascular scaffold versus drug-eluting stents in coronary artery disease: a meta-analysis.
    Nairooz R; Saad M; Sardar P; Aronow WS
    Heart; 2017 Jul; 103(14):1096-1103. PubMed ID: 28115471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of everolimus-eluting bioresorbable vascular scaffolds versus durable polymer everolimus-eluting metallic stents assessed at 1-year follow-up: A systematic review and meta-analysis of studies.
    Mukete BN; van der Heijden LC; Tandjung K; Baydoun H; Yadav K; Saleh QA; Doggen CJ; Abi Rafeh N; Le Jemtel TH; von Birgelen C
    Int J Cardiol; 2016 Oct; 221():1087-94. PubMed ID: 27448538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy.
    Ali ZA; Serruys PW; Kimura T; Gao R; Ellis SG; Kereiakes DJ; Onuma Y; Simonton C; Zhang Z; Stone GW
    Lancet; 2017 Aug; 390(10096):760-772. PubMed ID: 28732815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials.
    Cassese S; Byrne RA; Ndrepepa G; Kufner S; Wiebe J; Repp J; Schunkert H; Fusaro M; Kimura T; Kastrati A
    Lancet; 2016 Feb; 387(10018):537-544. PubMed ID: 26597771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temporal Trends in Adverse Events After Everolimus-Eluting Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: A Meta-Analysis of Randomized Controlled Trials.
    Montone RA; Niccoli G; De Marco F; Minelli S; D'Ascenzo F; Testa L; Bedogni F; Crea F
    Circulation; 2017 May; 135(22):2145-2154. PubMed ID: 28559495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds.
    Puricel S; Arroyo D; Corpataux N; Baeriswyl G; Lehmann S; Kallinikou Z; Muller O; Allard L; Stauffer JC; Togni M; Goy JJ; Cook S
    J Am Coll Cardiol; 2015 Mar; 65(8):791-801. PubMed ID: 25720622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis.
    Stone GW; Gao R; Kimura T; Kereiakes DJ; Ellis SG; Onuma Y; Cheong WF; Jones-McMeans J; Su X; Zhang Z; Serruys PW
    Lancet; 2016 Mar; 387(10025):1277-89. PubMed ID: 26825231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction).
    Brugaletta S; Gori T; Low AF; Tousek P; Pinar E; Gomez-Lara J; Scalone G; Schulz E; Chan MY; Kocka V; Hurtado J; Gomez-Hospital JA; Münzel T; Lee CH; Cequier A; Valdés M; Widimsky P; Serruys PW; Sabaté M
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):189-197. PubMed ID: 25616924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mid-term outcomes of bioresorbable vascular scaffolds vs second-generation drug-eluting stents in patients with acute coronary syndromes: A systematic review and meta-analysis.
    Ke J; Zhang H; Huang J; Lv P; Yan J
    Medicine (Baltimore); 2020 Mar; 99(10):e19458. PubMed ID: 32150103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of bioresorbable vascular scaffold Absorb BVS® in patients with stable coronary artery disease: one-year results with special focus on the hybrid bioresorbable vascular scaffolds and drug eluting stents treatment.
    Gil RJ; Bil J; Pawłowski T; Yuldashev N; Kołakowski L; Jańczak J; Jabłoński W; Paliński P
    Kardiol Pol; 2016; 74(7):627-33. PubMed ID: 26779846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three to four years outcomes of the absorb bioresorbable vascular scaffold versus second-generation drug-eluting stent: A meta-analysis.
    Goel S; Pasam RT; Chava S; Sharma A; Malik BA; Ayzenberg S; Frankel R; Shani J; Gidwani U
    Catheter Cardiovasc Interv; 2020 Feb; 95(2):216-223. PubMed ID: 31002216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioresorbable vascular scaffolds versus conventional drug-eluting stents across time: a meta-analysis of randomised controlled trials.
    Jackson-Smith E; Zioupos S; Banerjee P
    Open Heart; 2022 Oct; 9(2):. PubMed ID: 36288820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-Year Outcomes With the Absorb Bioresorbable Scaffold: Individual-Patient-Data Meta-Analysis From the ABSORB Randomized Trials.
    Ali ZA; Gao R; Kimura T; Onuma Y; Kereiakes DJ; Ellis SG; Chevalier B; Vu MT; Zhang Z; Simonton CA; Serruys PW; Stone GW
    Circulation; 2018 Jan; 137(5):464-479. PubMed ID: 29089314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mid- to long-term outcome of patients treated with everolimus-eluting bioresorbable vascular scaffolds: Data of the BVS registry Göttingen predominantly from ACS patients.
    Hellenkamp K; Becker A; Gabriel YD; Hasenfuß G; Hünlich M; Jacobshagen C; Schillinger W; Schroeter MR
    Int J Cardiol; 2017 May; 234():58-63. PubMed ID: 28258843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A hybrid strategy with bioresorbable vascular scaffolds and drug eluting stents for treating complex coronary lesions.
    Jabbour RJ; Ielasi A; Tanaka A; Leoncini M; Cortese B; Grigis G; Mitomo S; Regazzoli D; Di Palma G; Rapetto C; Tespili M; Colombo A; Latib A
    Cardiovasc Revasc Med; 2017; 18(5S1):S4-S9. PubMed ID: 28314675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents.
    Sorrentino S; Giustino G; Mehran R; Kini AS; Sharma SK; Faggioni M; Farhan S; Vogel B; Indolfi C; Dangas GD
    J Am Coll Cardiol; 2017 Jun; 69(25):3055-3066. PubMed ID: 28412389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcomes of bioresorbable vascular scaffold in ST-elevation myocardial infarction.
    de Hemptinne Q; Picard F; Ly HQ; Ibrahim R; Asgar AW; de Guise P; Doucet S; Dorval JF; Marquis-Gravel G; Levi M; L-L'allier P; Tanguay JF
    Acta Cardiol; 2018 Jun; 73(3):276-281. PubMed ID: 28954592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mid-term outcomes of the Absorb BVS versus second-generation DES: A systematic review and meta-analysis.
    Felix CM; van den Berg VJ; Hoeks SE; Fam JM; Lenzen M; Boersma E; Smits PC; Serruys PW; Onuma Y; van Geuns RJM
    PLoS One; 2018; 13(5):e0197119. PubMed ID: 29742143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Efficacy and Safety of Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stents: A Systematic Review and Meta-analysis.
    Zhang XL; Zhu L; Wei ZH; Zhu QQ; Qiao JZ; Dai Q; Huang W; Li XH; Xie J; Kang LN; Wang L; Xu B
    Ann Intern Med; 2016 Jun; 164(11):752-63. PubMed ID: 27042809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly (l-lactic acid) bioresorbable scaffolds versus metallic drug-eluting stents for the treatment of coronary artery disease: A meta-analysis of 11 randomized trials.
    Verdoia M; Kedhi E; Suryapranata H; Galasso G; Dudek D; De Luca G
    Catheter Cardiovasc Interv; 2020 Oct; 96(4):813-824. PubMed ID: 31730255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.